

Conference call interim report

Invitation to attend Vitrolife's conference call regarding presentation of the interim report for the period January – June 2017. The presentation will be held in English.

Time: Friday July 14, 2017 at 10.00 a.m. CET.

Registration can preferably be done 10-15 minutes before the conference start time on:

Sweden dial in number: +46 (0)8 5052 0337

UK dial in number: +44 (0)20 7162 9960

Conference name: Vitrolife, conference ID: 962328

Vitrolife participants:

Thomas Axelsson, CEO

Mikael Engblom, CFO

The press release for Vitrolife's interim report will be released at 8.30 CET on the same day.

Before the conference call, slides will be available at the company web page,

<http://www.vitrolife.com>.

A recorded version of the presentation will be available for seven days on number +46 (0)8 5052 0333 (Sweden) or +44 (0)20 7031 4064 (UK), access code 962328.

Gothenburg, July 14, 2017

VITROLIFE AB (publ)

Contact:

Mikael Engblom, CFO, phone +46 (0)31 721 80 14

Vitrolife is an international medical device Group. Vitrolife develops, produces and markets products for assisted reproduction. Work is also carried out to enable the use and handling of stem cells for therapeutic purposes.

Vitrolife has about 350 employees and the company's products are sold in about 110 markets. The company is headquartered in Gothenburg, Sweden, and there are also offices in Australia, China, Denmark, France, Germany, Italy, Japan, United Kingdom and USA. The Vitrolife share is listed on NASDAQ Stockholm.

Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate identity number 556354-3452. Tel: +46 31 721 80 00. Fax: +46 31 721 80 99.
E-mail: info@vitrolife.com. Website: www.vitrolife.com.

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.